Clinical outcome of cardiac surgery in patients with remitted or active hepatocellular carcinoma

Surg Today. 2021 Sep;51(9):1456-1463. doi: 10.1007/s00595-021-02239-z. Epub 2021 Feb 8.

Abstract

Purpose: Hepatocellular carcinoma (HCC) is one of the most common primary cancers worldwide. HCC has unique characteristics such as co-existing chronic liver damage and a high recurrence rate. A negative impact on the surgical outcome due to these backgrounds could be expected. We aimed to evaluate the clinical outcomes of cardiac surgery in these patients.

Methods: Between January 2000 and December 2019, 16 patients with remitted cancer and 5 patients with active HCC who underwent open heart surgery were studied. The clinical data were retrospectively evaluated from hospital records. Follow-up information was collected via telephone interviews.

Results: The major cause of HCC was viral hepatitis. Eighteen patients (86%) were classified as having Child-Pugh class A cirrhosis. The mean model of end-stage liver disease (MELD) score was 7.2 ± 5.2. There was no 30-day mortality. During follow-up, 11 patients died due to HCC. The 1-, 3-, and 5-year survival rates were 80.0, 42.5, and 22.3%, respectively. A univariate analysis identified a higher preoperative MELD score and lower serum cholinesterase levels as prognostic factors for long-term survival.

Conclusion: We could safely perform cardiac surgery in selected patients with remitted and active HCC. The postoperative life expectancy of these patients was limited but acceptable.

Keywords: Cardiac surgery; Hepatocellular carcinoma; Liver cirrhosis; Outcome.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Carcinoma, Hepatocellular / complications*
  • Cardiac Surgical Procedures / methods
  • Female
  • Follow-Up Studies
  • Heart Diseases / complications
  • Heart Diseases / surgery*
  • Humans
  • Life Expectancy
  • Liver Neoplasms / complications*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome